Loading...

We've got a brand new version of Simply Wall St! Try it out

Sona Nanotech

CNSX:SONA
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SONA
CNSX
CA$12M
Market Cap
  1. Home
  2. CA
  3. Healthcare
Company description

Sona Nanotech Inc. manufactures gold nanorod products for diagnostic test products and medical treatment applications. The last earnings update was 79 days ago. More info.


Add to Portfolio Compare Print
  • Sona Nanotech has significant price volatility in the past 3 months.
SONA Share Price and Events
7 Day Returns
-4.4%
CNSX:SONA
-3.8%
CA Medical Equipment
1.2%
CA Market
1 Year Returns
-
CNSX:SONA
-6.4%
CA Medical Equipment
-0.2%
CA Market
SONA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sona Nanotech (SONA) -4.4% 2.4% -15.7% - - -
CA Medical Equipment -3.8% 0.1% -5.4% -6.4% -43.4% -84.5%
CA Market 1.2% 4.2% 1.5% -0.2% 8.4% 1.8%
1 Year Return vs Industry and Market
  • No trading data on SONA.
  • No trading data on SONA.
Price Volatility
Industry
5yr Volatility vs Market

SONA Value

 Is Sona Nanotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Sona Nanotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sona Nanotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sona Nanotech. This is due to cash flow or dividend data being unavailable. The share price is CA$0.215.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sona Nanotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sona Nanotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:SONA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$-0.13
CNSX:SONA Share Price ** CNSX (2019-09-13) in CAD CA$0.22
North America Medical Equipment Industry PE Ratio Median Figure of 67 Publicly-Listed Medical Equipment Companies 41.51x
Canada Market PE Ratio Median Figure of 538 Publicly-Listed Companies 14.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sona Nanotech.

CNSX:SONA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:SONA Share Price ÷ EPS (both in CAD)

= 0.22 ÷ -0.13

-1.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sona Nanotech is loss making, we can't compare its value to the North America Medical Equipment industry average.
  • Sona Nanotech is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Sona Nanotech's expected growth come at a high price?
Raw Data
CNSX:SONA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Medical Equipment Industry PEG Ratio Median Figure of 58 Publicly-Listed Medical Equipment Companies 2.17x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.98x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sona Nanotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sona Nanotech's assets?
Raw Data
CNSX:SONA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$-0.01
CNSX:SONA Share Price * CNSX (2019-09-13) in CAD CA$0.22
Canada Medical Equipment Industry PB Ratio Median Figure of 15 Publicly-Listed Medical Equipment Companies 5.47x
Canada Market PB Ratio Median Figure of 2,452 Publicly-Listed Companies 1.44x
CNSX:SONA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:SONA Share Price ÷ Book Value per Share (both in CAD)

= 0.22 ÷ -0.01

-23.8x

* Primary Listing of Sona Nanotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sona Nanotech has negative assets, we can't compare the value of its assets to the CA Medical Equipment industry average.

Next steps:

  1. Take a look at our analysis of SONA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Sona Nanotech's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Medical Equipment industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Sona Nanotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Sona Nanotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SONA Future Performance

 How is Sona Nanotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sona Nanotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sona Nanotech expected to grow at an attractive rate?
  • Unable to compare Sona Nanotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sona Nanotech's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Sona Nanotech's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:SONA Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
North America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:SONA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:SONA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 -2 -6
2019-01-31 -2 -5
2018-10-31 -1 -5
2018-07-31 -1 -1
2017-10-31 0 0
2016-12-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sona Nanotech is high growth as no earnings estimate data is available.
  • Unable to determine if Sona Nanotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:SONA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sona Nanotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:SONA Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 -0.13
2019-01-31 -0.15
2018-10-31 -0.19
2018-07-31 -0.11
2017-10-31 -0.03
2016-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sona Nanotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of SONA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Sona Nanotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Sona Nanotech's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sona Nanotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sona Nanotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SONA Past Performance

  How has Sona Nanotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sona Nanotech's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sona Nanotech does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Sona Nanotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sona Nanotech's 1-year growth to the North America Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Sona Nanotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sona Nanotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:SONA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 -5.58 1.37 0.07
2019-01-31 -5.40 1.18 0.11
2018-10-31 -5.20 1.02 0.09
2018-07-31 -0.92 0.79 0.14
2017-10-31 -0.45 0.52 -0.06
2016-12-31 -0.64 0.63 -0.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sona Nanotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Sona Nanotech has efficiently used its assets last year compared to the North America Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sona Nanotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sona Nanotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sona Nanotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SONA Health

 How is Sona Nanotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sona Nanotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sona Nanotech's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Sona Nanotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sona Nanotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Sona Nanotech has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sona Nanotech Company Filings, last reported 4 months ago.

CNSX:SONA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 -0.48 1.30 0.91
2019-01-31 -0.14 1.19 1.19
2018-10-31 0.20 1.09 1.81
2018-07-31 -1.11 0.60 0.08
2017-10-31 -0.80 0.33 0.17
2016-12-31 -0.61 0.19 0.04
  • Sona Nanotech has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Sona Nanotech's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sona Nanotech has less than a year of cash runway based on current free cash flow.
  • Sona Nanotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 69.2% each year.
X
Financial health checks
We assess Sona Nanotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sona Nanotech has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SONA Dividends

 What is Sona Nanotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sona Nanotech dividends.
If you bought CA$2,000 of Sona Nanotech shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sona Nanotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sona Nanotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:SONA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 1.2%
Canada Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sona Nanotech has not reported any payouts.
  • Unable to verify if Sona Nanotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sona Nanotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sona Nanotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sona Nanotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sona Nanotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sona Nanotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SONA Management

 What is the CEO of Sona Nanotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Darren Rowles
COMPENSATION CA$153,171
AGE 39
TENURE AS CEO 1.9 years
CEO Bio

Mr. Darren Rowles has been President and Chief Executive Officer at Sona Nanotech Limited since October 2017. Mr. Rowles has almost 15 years of experience in the diagnostic and nanoparticle industry and previously worked for one of the leading providers of technologies to the global diagnostics market, where he specialised in product manufacture and development in the area of noble metal nanoparticles and lateral flow diagnostics. Mr. Rowles is a key opinion leader at industry seminars and conferences and acts as an advisory board member to the World Gold Council. Mr. Rowles holds a BSC in Biomedical Science and Toxicology from the University of Wales Institute Cardiff (2003) and a Master of Business Administration from the University of Bath (2017).

CEO Compensation
  • Insufficient data for Darren to compare compensation growth.
  • Darren's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Sona Nanotech management team in years:

3.8
Average Tenure
  • The tenure for the Sona Nanotech management team is about average.
Management Team

Darren Rowles

TITLE
President & CEO
COMPENSATION
CA$153K
AGE
39
TENURE
1.9 yrs

Rob Randall

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$77K
AGE
56
TENURE
1.8 yrs

Kulbir Singh

TITLE
CTO & Founder
TENURE
5.7 yrs

Mike McAlduff

TITLE
Director of R&D & Production and Founder
TENURE
5.7 yrs

Gerrard Marangoni

TITLE
Product Science Advisor & Founder
Board of Directors Tenure

Average tenure and age of the Sona Nanotech board of directors in years:

6.6
Average Tenure
61
Average Age
  • The tenure for the Sona Nanotech board of directors is about average.
Board of Directors

Wade Dawe

TITLE
Chairman of the Board
COMPENSATION
CA$16K
AGE
49

Robert McKay

TITLE
Director
COMPENSATION
CA$14K
TENURE
6.7 yrs

Catherine Murphy

TITLE
Member of Advisory Board

Shine Zhang

TITLE
Member of Advisory Board

Dan Whittaker

TITLE
Director
AGE
61

Zeph Mbugua

TITLE
Director
COMPENSATION
CA$14K
AGE
69
TENURE
6.6 yrs

Michael Gross

TITLE
Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Sona Nanotech individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
19. Jul 19 Buy Numus Financial Company 16. Jul 19 16. Jul 19 367,200 CA$0.25 CA$91,800
19. Jul 19 Buy Brigus Capital Incorporated Company 16. Jul 19 16. Jul 19 1,072,812 CA$0.25 CA$268,203
19. Jul 19 Buy Robert William Randall Individual 16. Jul 19 16. Jul 19 120,000 CA$0.25 CA$30,000
28. Mar 19 Buy Birch Point Holdings, Inc. Company 26. Mar 19 26. Mar 19 5,000 CA$0.27 CA$1,350
21. Mar 19 Buy Birch Point Holdings, Inc. Company 20. Mar 19 20. Mar 19 20,000 CA$0.28 CA$5,590
14. Mar 19 Buy Birch Point Holdings, Inc. Company 14. Mar 19 14. Mar 19 75,000 CA$0.30 CA$22,500
08. Feb 19 Buy Birch Point Holdings, Inc. Company 08. Feb 19 08. Feb 19 5,000 CA$0.31 CA$1,525
08. Feb 19 Buy Daniel Whittaker Individual 08. Feb 19 08. Feb 19 25,000 CA$0.30 CA$7,500
14. Jan 19 Sell Birch Point Holdings, Inc. Company 09. Jan 19 09. Jan 19 -158,207 CA$0.16 CA$-25,313
01. Jan 19 Buy Birch Point Holdings, Inc. Company 31. Dec 18 31. Dec 18 29,500 CA$0.23 CA$6,785
01. Jan 19 Buy Daniel Whittaker Individual 31. Dec 18 31. Dec 18 80,000 CA$0.23 CA$18,400
28. Dec 18 Buy Birch Point Holdings, Inc. Company 24. Dec 18 28. Dec 18 156,000 CA$0.25 CA$38,613
11. Oct 18 Buy Harold Megann Individual 28. Sep 18 28. Sep 18 380,000 CA$0.25 CA$95,000
12. Oct 18 Buy Andrew Smith Individual 28. Sep 18 28. Sep 18 100,000 CA$0.25 CA$25,000
11. Oct 18 Buy Robert McKay Individual 28. Sep 18 28. Sep 18 300,000 CA$0.25 CA$75,000
11. Oct 18 Buy Numus Financial Company 28. Sep 18 28. Sep 18 440,000 CA$0.25 CA$110,000
03. Oct 18 Buy Daniel Whittaker Individual 28. Sep 18 28. Sep 18 200,000 CA$0.25 CA$50,000
X
Management checks
We assess Sona Nanotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sona Nanotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SONA News

Simply Wall St News

Do Insiders Own Lots Of Shares In Sona Nanotech Inc. (CNSX:SONA)?

Check out our latest analysis for Sona Nanotech CNSX:SONA Ownership Summary, September 3rd 2019 What Does The Institutional Ownership Tell Us About Sona Nanotech? … We can see that Sona Nanotech does have institutional investors; and they hold 8.9% of the stock. … General Public Ownership The general public -- mostly retail investors -- own 73% of Sona Nanotech.

Simply Wall St -

We Think Sona Nanotech (CNSX:SONA) Has Us A Very Heavy Debt Load

CNSX:SONA Historical Debt, July 11th 2019 How Strong Is Sona Nanotech's Balance Sheet? … Zooming in on the latest balance sheet data, we can see that Sona Nanotech had liabilities of CA$2.28m due within 12 months and liabilities of CA$700.9k due beyond that. … Because it carries more debt than cash, we think it's worth watching Sona Nanotech's balance sheet over time.

Simply Wall St -

SONA Company Info

Description

Sona Nanotech Inc. manufactures gold nanorod products for diagnostic test products and medical treatment applications. Its products portfolio comprises Gemini 650NM, Gemini 700NM, Gemini 750NM, Gemini 800NM, Gemini 850NM, Gemini 900NM, Gemini 950NM, and Gemini 1050NM, as well as Gemini nanorods kit. The company has collaborations with Soma Bioscience Ltd. to produce diagnostic tests; Anteo Diagnostics Limited to develop products that improve the development and performance of lateral flow immunoassays; and University of Birmingham to develop nanorods for tissue imaging. Sona Nanotech Inc. is based in Halifax, Canada.

Details
Name: Sona Nanotech Inc.
SONA
Exchange: CNSX
Founded:
CA$11,537,495
53,662,769
Website: http://www.sonanano.com
Address: Sona Nanotech Inc.
Purdy’s Wharf Tower II,
Suite 2001,
Halifax,
Nova Scotia, B3J 3R7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX SONA Common Shares Canadian National Stock Exchange CA CAD 04. Oct 2018
OTCPK LMTC.F Common Shares Pink Sheets LLC US USD 04. Oct 2018
Number of employees
Current staff
Staff numbers
0
Sona Nanotech employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/15 01:36
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/06/28
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.